Post-Marketing Safety Data for Brexanolone (Zulresso)
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
NPR’s 1A Live hosts an episode focusing on perinatal depression, including information on the new medication zuranolone for the treatment of postpartum depression.
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment.
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]